Biocartis Group NV: Disclosure of a transparency notification

PRESS RELEASE: REGULATED INFORMATION

Wednesday 13 July 2016, 07:00 CEST

Disclosure of a transparency notification

(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)

Mechelen, Belgium, 13 July 2016 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 11 July 2016 (the 'Notification'), indicating that the shareholding of Coöperatieve AESCAP Venture I U.A. (which is controlled by AESCAP Venture Management B.V.) has decreased below the 3% notification threshold.

The Notification contains the following information:

·        Reason for the Notification: disposal of voting securities or voting rights and downward crossing of the lowest threshold.

·        Notification by: a parent undertaking or a controlling person.

·        Persons subject to the notification requirement: Coöperatieve AESCAP Venture I U.A., Barbara Strozzilaan 101, 1083HN, The Netherlands and AESCAP Venture Management B.V., Barbara Strozzilaan 101, 1083HN, The Netherlands.

·        Transaction date: 28 June 2016.

·        Threshold that is crossed: 3%.

·        Denominator: 40,589,188.

·        Chain of controlled undertakings through which the holding was effectively held:

AESCAP Venture Management B.V. controls Coöperatieve AESCAP Venture I U.A.

AESCAP Venture Management B.V. is not a controlled entity.

The Notification is available here on the website of the Company.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

 ----- END ----

For more information:
Renate Degrave, Corporate Communications & Investor Relations
rdegrave@biocartis.com
+32 15 631 729

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has five oncology tests and two infectious disease tests on the market. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.